Given the context-dependent role of CHD1 in prostate tumors, genes showing co-occurrence (SPOP or MAP3K7) or mutual exclusivity (ERG and PTEN) should also be considered as influence factors in these clinical studies. This evidence concerns the gene ERG and prostate neoplasm.